GGrantIndex
← Search

ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS

$0M01FY2000RRNIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Abstract

This multicenter, Phase II, clinical trial will examine the virologic efficacy and safety of the combinations of Indinavir plus DMP-166 (experimental non-nucleoside reverse transcriptase inhibitor) vs. Indinavir plus DMP-166 plus 1592&89 (experimental carbocyclic nucleoside analog, reverse transcriptase inhibitor) vs. Indinavir plus 1592U89 in patients with HIV.

View original record on NIH RePORTER →